Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business clinical trial

Novartis del-desiran Phase III failure fallout

Analysis based on 21 articles · First reported Sep 08, 2026 · Last updated Sep 11, 2026

Sentiment
-25
Attention
6
Articles
21
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The trial failure triggered a sharp sell-off in Novartis shares, wiping tens of billions of dollars of market value and raising doubts about the company's M&A-driven pipeline strategy ahead of looming patent expiries. It also spilled over to other muscular dystrophy drug developers such as Dyne Therapeutics and Sarepta Therapeutics, while keeping investor focus on upcoming remibrutinib data as the next key catalyst.

pharmaceuticals biotechnology healthcare

Novartis announced on September 8, 2026 that its Phase III HARBOR study of del-desiran, an antibody oligonucleotide conjugate for myotonic dystrophy type 1 (DM1), failed to show statistically significant improvement versus placebo on the primary endpoint of video hand opening time. The drug was acquired through Novartis' roughly $12 billion purchase of Avidity Biosciences. It was the second major pipeline setback in days, following the failure of the cholesterol drug pelacarsen, and Novartis shares fell about 9-11% in one of the company's worst trading days on record, reportedly wiping roughly 24 billion Switzerland — Swiss francs (about $29.6 billion) off its market value and erasing gains made since the start of the year. The failure increases pressure on CEO Shar Narasimhan and his M&A-led pipeline strategy, with investors including Artisan Partners Asset Management, Union Investment, Verso Investment Management, DJE Kapital, Bellevue Asset Management and Arctic Asset Management questioning the Avidity deal and calling for more disciplined, smaller bolt-on acquisitions and better board oversight. Novartis reiterated its 5-6% five-year sales CAGR guidance for 2025-2030 and continues to advance other Avidity AOC therapies, including del-zota, which received FDA priority review in DMD44, and del-brax in FSHD. The next major catalyst is detailed remibrutinib data in relapsing multiple sclerosis expected at a medical meeting in October. The news also weighed on other muscular dystrophy developers, with Dyne Therapeutics and Sarepta Therapeutics shares falling sharply in US premarket trading.

100 Novartis announced trial failure
95 Novartis failed late-stage study
92 Novartis paused trials
90 Novartis wiped market value
90 Novartis shares slumped
72 Artisan Partners Asset Management called for board shake-up Novartis
70 Novartis missed pipeline readouts
65 Novartis faced investor scrutiny
50 Novartis committed acquisitions
40 Novartis reiterated full-year guidance
40 Dyne Therapeutics shares fell
40 Sarepta Therapeutics shares fell
+ 2 more actions View on Dashboard
stock
Novartis is the central entity of the event; the del-desiran Phase III failure and prior pelacarsen setback erased roughly $30 billion in market value and intensified investor scrutiny of its M&A strategy and pipeline.
Importance 100.0 Sentiment -45.0
per
CEO Shar Narasimhan faces heightened investor pressure over his M&A-led pipeline strategy, though shareholders largely stopped short of calling for his removal.
Importance 80.0 Sentiment -25.0
priv
Acquired by Novartis for $12 billion; its lead drug del-desiran failed, undermining the value of the acquisition.
Importance 70.0 Sentiment -60.0
stock
Avidity was acquired by Novartis for about $12 billion, and the failure of del-desiran, one of its lead AOC assets, has dented confidence in the value and rationale of that acquisition.
Importance 70.0 Sentiment -30.0
priv
Novartis shareholder whose portfolio manager Michael Hannig suggested deals worth $5 billion to $10 billion for late-stage assets to rebuild confidence.
Importance 40.0 Sentiment 0.0
priv
Novartis investor whose healthcare analyst Guy Bettschart-Ghassabi noted the HARBOR study was designed before the Avidity purchase and reaffirmed confidence in management.
Importance 35.0 Sentiment 0.0
priv
Novartis investor whose portfolio manager Daniel Bolanowski said the sell-off suggested a deeper trust issue about business development, though calling for management changes is premature.
Importance 35.0 Sentiment -10.0
stock
Artisan Partners Asset Management, a major Novartis shareholder, called for a board shake-up to improve M&A oversight while still supporting CEO Shar Narasimhan.
Importance 35.0 Sentiment 0.0
priv
Novartis shareholder whose analyst commented on the failure, reflecting investor concerns.
Importance 30.0 Sentiment -40.0
per
Analyst at Verso Investment Management, provided critical commentary on the trial failure.
Importance 30.0 Sentiment -40.0
priv
Analyst firm noted worries over post-2030 growth will re-emerge.
Importance 30.0 Sentiment -30.0
per
Jefferies analyst who commented on the growth concerns.
Importance 30.0 Sentiment -30.0
priv
Novartis and Roche shareholder whose lead manager Gillian Hollenstein said confidence will take time to return and that smaller bolt-on acquisitions would have been preferable.
Importance 30.0 Sentiment -10.0
per
Novartis' development chief and CMO publicly framed the HARBOR failure as part of scientific progress and said the company is evaluating the full dataset and development path for del-desiran.
Importance 30.0 Sentiment -10.0
stock
Dyne Therapeutics shares fell about 30% in US premarket trading as the del-desiran failure weighed on sentiment toward muscular dystrophy drug developers.
Importance 25.0 Sentiment -40.0
+ 17 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.